 Fallopian Tube Neoplasms
"Fallopian Tube Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.
| Descriptor ID |
D005185
|
| MeSH Number(s) |
C04.588.945.418.365 C13.351.500.056.390.390 C13.351.937.418.365
|
| Concept/Terms |
Fallopian Tube Neoplasms- Fallopian Tube Neoplasms
- Fallopian Tube Neoplasm
- Neoplasm, Fallopian Tube
- Neoplasms, Fallopian Tube
Fallopian Tube Cancer- Fallopian Tube Cancer
- Cancer, Fallopian Tube
- Cancers, Fallopian Tube
- Fallopian Tube Cancers
- Cancer of the Fallopian Tube
|
Below are MeSH descriptors whose meaning is more general than "Fallopian Tube Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Fallopian Tube Neoplasms".
This graph shows the total number of publications written about "Fallopian Tube Neoplasms" by people in this website by year, and whether "Fallopian Tube Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 2002 | 1 | 1 | 2 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2008 | 2 | 0 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 1 | 0 | 1 | | 2011 | 3 | 0 | 3 | | 2012 | 2 | 0 | 2 | | 2014 | 2 | 0 | 2 | | 2015 | 3 | 0 | 3 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2019 | 4 | 0 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Fallopian Tube Neoplasms" by people in Profiles.
-
Rajagopal PS, Nielsen S, Olopade OI. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan. JAMA Netw Open. 2019 08 02; 2(8):e1910142.
-
Kurnit KC, Lu KH, Westin SN. Rapidly Changing Landscape of Fallopian Tube Carcinoma. J Oncol Pract. 2019 07; 15(7):383-384.
-
Rodriguez GC, Kauderer J, Hunn J, Thaete LG, Watkin WG, Russell S, Yozwiak M, Basil J, Hurteau J, Lele S, Modesitt SC, Zivanovic O, Zhang HH, Bartels PH, Alberts DS. Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. Cancer Prev Res (Phila). 2019 06; 12(6):401-412.
-
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648.
-
von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, Bradley WH, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 03; 144(3):459-467.
-
Eckert MA, Pan S, Hernandez KM, Loth RM, Andrade J, Volchenboum SL, Faber P, Montag A, Lastra R, Peter ME, Yamada SD, Lengyel E. Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. Cancer Discov. 2016 12; 6(12):1342-1351.
-
Ritterhouse LL, Nowak JA, Strickland KC, Garcia EP, Jia Y, Lindeman NI, Macconaill LE, Konstantinopoulos PA, Matulonis UA, Liu J, Berkowitz RS, Nucci MR, Crum CP, Sholl LM, Howitt BE. Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol. 2016 08; 29(8):893-903.
-
Landrum LM, Brady WE, Armstrong DK, Moore KN, DiSilvestro PA, O'Malley DM, Tenney ME, Rose PG, Fracasso PM. A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):204-9.
-
Ferriss JS, Java JJ, Bookman MA, Fleming GF, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente MP, Burger RA. Ascites predicts treatment benefit of bevacizumab in front-line therapy of advanced epithelial ovarian, fallopian tube and peritoneal cancers: an NRG Oncology/GOG study. Gynecol Oncol. 2015 Oct; 139(1):17-22.
-
Hirte H, Lheureux S, Fleming GF, Sugimoto A, Morgan R, Biagi J, Wang L, McGill S, Ivy SP, Oza AM. A phase 2 study of cediranib in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: a trial of the Princess Margaret, Chicago and California Phase II Consortia. Gynecol Oncol. 2015 Jul; 138(1):55-61.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|